

Daiichi Sankyo

BioEU Spring meeting

March 18-20th, 2024



Daiichi-Sankyo

Confidential. Use and distribution of this presentation must be approved by PMRT or Legal.

Passion for Innovation.
Compassion for Patients.™

About Daiichi Sankyo



Global
innovative
pharmaceutical
company



27th
Ranked among top global
pharmaceutical companies*



120+
years of expertise



17,000+
employees
around the world



Ground presence in
29 countries/regions



Manufacturing in
6 countries/regions



18 R&D
sites in key locations



¥1,278.5 billion**
FY2022 consolidated revenue

* [2023 Pharm Exec Top 50 Companies](#) | Pharmaceutical Executive, 06-10-2023, Volume 43, Issue 6

** Consolidated Financial Results for Fiscal 2022 (Year Ended March 31, 2023). FOREX rate applied for U.S. based affiliates revenue: USD/JPY = 135.48

Strategic Areas of Interest (Technology)

Oncology

- I. Novel immune-oncology targets focused on polymorphonuclear leukocyte-derived suppressor cells, innate lymphoid cells or enhancement of tumor antigenicity (for which mechanisms are confirmed in human-derived samples)
- II. Novel, biologically-tractable, tumor-specific antigens and their binders such as monoclonal antibody/antibody mimetics/Fab/scFv/sdAb for ADC, bispecific antibody and CAR-T
- III. Novel technologies for adoptive T cell therapy
 - a) Novel molecular targets/mechanisms to potentiate T-cell functions, b) Novel molecular targets/mechanisms to enhance efficacy in solid tumor, c) Novel conditional activation machinery at tumor sites (ex. On/Off switch)

Non-Oncology

- I. Novel disease relevant target identification research by using patient tissue samples or genetical analysis for the following target diseases (* both are neuroinflammation perspective)
 - a) Immune diseases: Chronic inflammatory demyelinating polyneuropathy, Systemic sclerosis, ANCA-associated vasculitis, Progressive multiple sclerosis and Idiopathic pulmonary fibrosis
 - b) Neurodegenerative diseases*: Alzheimer's disease, Parkinson's disease (Brain lipid and glucose metabolism aspect)
 - c) Psychiatric diseases*: Schizophrenia, Autism spectrum disorder and Anxiety
 - d) Chronic heart failure (HFrEF and HFpEF) and NASH
 - e) Rare diseases (for gene therapy): CNS, liver (mono or double genetic)
 - f) Ophthalmological disorders (dry AMD, RP and PDR)
- II. Novel in vitro (iPSC derived) and in vivo models that recapture human pathological mechanisms/conditions of immune, CNS and NASH
- III. Drug delivery technologies for siRNAs with conjugation format to brain, heart, lung (macrophage) & kidney (tubular cells)
- IV. Novel RNA editing technologies (not RNase2, Ago2 & ADAR) with CNS diseases
- V. AAV platform: new capsid library (liver target)

Daiichi Sankyo Sponsored Research Program

Focus on early-stage drug discovery and life sciences research (fits strategic areas of interest)

Guidelines for Application

- ❖ Application is on email basis. Please send us one page summary of the proposal (only non-confidential information) at the program office (OpenInnovation@daiichisankyo.co.jp).
- ❖ Eligibility: Researchers affiliated with universities and research institutions, who have ideas which may lead to drug discovery. The program is not open to undergraduate or graduate students.
- ❖ Research Budget: up to \$230,000 for one year including overhead/indirect costs
- ❖ Term: 1-2 years. Successful program(s) will be considered for staging into collaborative research.
- ❖ Selection Criteria:
 - Matching needs (Research interests)
 - Originality and uniqueness of research
 - Drug discovery potential
 - Feasibility of research plan
 - Non-redundancy with Daiichi Sankyo's internal research projects and current collaboration
- ❖ Deadline: Rolling application (until September 2024)